Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Latz

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
Seminars in Vascular Surgery|July 22, 1998
Endovascular therapy for upper extremity injuryT Ohki, F J Veith, C Kraas, et al.
Journal of Medicinal Chemistry|October 1, 1989
Substituted 5-amino-4,5,6,7-tetrahydroindazoles as partial ergoline structures with dopaminergic activityL A McQuaid, J E Latz, J A Clemens, et al.
Cancer Chemotherapy and Pharmacology|November 18, 2008
Pharmacokinetic evaluation of platinum derived from cisplatin administered alone and with pemetrexed in head and neck cancer patientsPol M Specenier, Tudor Ciuleanu, Jane E Latz, et al.
Journal of Periodontal Research|November 22, 2017
Crystalline structure of pulverized dental calculus induces cell death in oral epithelial cellsS M Ziauddin, A Yoshimura, J L Montenegro Raudales, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 1, 2010
Randomized, double-blinded, multicenter, phase II study of pemetrexed, carboplatin, and bevacizumab with enzastaurin or placebo in chemonaïve patients with stage IIIB/IV non-small cell lung cancer: Hoosier Oncology Group LUN06-116Erin M Casey, Wael Harb, Daniel Bradford, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 13, 2010
Pemetrexed safety and pharmacokinetics in patients with third-space fluidNicolas J Dickgreber, Jens Benn Sorensen, Luis G Paz-Ares, et al.
Cancer Chemotherapy and Pharmacology|December 14, 2011
A phase I dose-escalation and pharmacokinetic study of enzastaurin and erlotinib in patients with advanced solid tumorsSukhmani K Padda, Yelena Krupitskaya, Laveena Chhatwani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 27, 2007
A phase I and pharmacokinetic study of pemetrexed plus irinotecan in patients with advanced solid malignanciesEric K Rowinsky, Muralidhar Beeram, Lisa A Hammond, et al.
The Journal of Experimental Medicine|July 4, 2001
Molecular genetic analysis of an endotoxin nonresponder mutant cell line: a point mutation in a conserved region of MD-2 abolishes endotoxin-induced signalingA B Schromm, E Lien, P Henneke, et al.
Lung Cancer (Amsterdam, Netherlands)|July 20, 2012
A phase II study of enzastaurin in combination with erlotinib in patients with previously treated advanced non-small cell lung cancerChristelle Clément-Duchêne, Ronald B Natale, Thierry Jahan, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Seminars in Vascular Surgery|July 22, 1998
Endovascular therapy for upper extremity injuryT Ohki, F J Veith, C Kraas, et al.
Journal of Medicinal Chemistry|October 1, 1989
Substituted 5-amino-4,5,6,7-tetrahydroindazoles as partial ergoline structures with dopaminergic activityL A McQuaid, J E Latz, J A Clemens, et al.
Cancer Chemotherapy and Pharmacology|November 18, 2008
Pharmacokinetic evaluation of platinum derived from cisplatin administered alone and with pemetrexed in head and neck cancer patientsPol M Specenier, Tudor Ciuleanu, Jane E Latz, et al.
Journal of Periodontal Research|November 22, 2017
Crystalline structure of pulverized dental calculus induces cell death in oral epithelial cellsS M Ziauddin, A Yoshimura, J L Montenegro Raudales, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 1, 2010
Randomized, double-blinded, multicenter, phase II study of pemetrexed, carboplatin, and bevacizumab with enzastaurin or placebo in chemonaïve patients with stage IIIB/IV non-small cell lung cancer: Hoosier Oncology Group LUN06-116Erin M Casey, Wael Harb, Daniel Bradford, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 13, 2010
Pemetrexed safety and pharmacokinetics in patients with third-space fluidNicolas J Dickgreber, Jens Benn Sorensen, Luis G Paz-Ares, et al.
Cancer Chemotherapy and Pharmacology|December 14, 2011
A phase I dose-escalation and pharmacokinetic study of enzastaurin and erlotinib in patients with advanced solid tumorsSukhmani K Padda, Yelena Krupitskaya, Laveena Chhatwani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 27, 2007
A phase I and pharmacokinetic study of pemetrexed plus irinotecan in patients with advanced solid malignanciesEric K Rowinsky, Muralidhar Beeram, Lisa A Hammond, et al.
The Journal of Experimental Medicine|July 4, 2001
Molecular genetic analysis of an endotoxin nonresponder mutant cell line: a point mutation in a conserved region of MD-2 abolishes endotoxin-induced signalingA B Schromm, E Lien, P Henneke, et al.
Lung Cancer (Amsterdam, Netherlands)|July 20, 2012
A phase II study of enzastaurin in combination with erlotinib in patients with previously treated advanced non-small cell lung cancerChristelle Clément-Duchêne, Ronald B Natale, Thierry Jahan, et al.
Pageof 3